Wayne Breer, MD
Dermatology · Chesterfield, MONPI 1255324703
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.1% of the total across 682 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 23.6% — the pattern of someone who eats at a lot of different presentations.
Across 682 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Johnson & Johnson$1K
- Lilly USA, LLC$851
- Pfizer$587
- UCB, Inc.$578
- Sun Pharmaceutical Industries Inc.$573
- plus $6K from 34 others
What the payments were for
- Speaking & faculty fees$971%
- Food & beverage$12,05695%
- Education$5284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$359
- Skyrizi$352
- VTAMA$249
- SOFDRA$138
- Rinvoq$123
- Kerecis Omega3 SurgiClose$120
- Kerecis Omega3 GraftGuide$120
- NEMLUVIO$117
- Otezla$115
- Seysara$103
How this compares
$12,680 in reported general payments places this provider in the 80th percentile of 263 dermatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 12 | $87,481 |
| Fluorouracil | 24 | $2,121 |
| Metronidazole | 25 | $1,347 |
| Clobetasol Propionate | 31 | $1,313 |
| Clobetasol EmollientClobetasol Propionate/Emoll | 15 | $986 |
| Desonide | 13 | $734 |
| Triamcinolone Acetonide | 40 | $532 |
| Ketoconazole | 28 | $402 |
| Mupirocin | 59 | $393 |
| Doxycycline Hyclate | 18 | $102 |
| Amoxicillin | 22 | $64 |
| Terbinafine Hcl | 15 | $54 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Chesterfield
- Lawrence SamuelsChesterfield$19K
- Daniel RingChesterfield$19K
- Laura WagnerChesterfield$16K
- Pooja DorwardChesterfield$10K
- Brian KimSaint Louis$861K
- Elaine SiegfriedSaint Louis$856K
- Craig LeonardiSaint Louis$569K
- Jonathan CleaverKirksville$483K
- Mary GeorgeSaint Louis$400K
- David CleaverKirksville$371K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.